Charter Life Sciences

Charter operates as a specialized venture capital firm, not a family office. It raises capital from external limited partners and deploys it into early-stage life-science companies. There is no public record linking it to a single-family balance sheet.

The firm concentrates on Seed and Series A rounds, with the ability to follow on through later clinical-stage financings. Its model is built around entering early enough to shape board composition and clinical strategy, then supporting portfolio companies through regulatory milestones.

Charter draws heavily on the California and Massachusetts life-science ecosystems — specifically academic medical centers, NIH-funded principal investigators, and the technology-transfer offices of research universities. Its co-investor network includes other specialist life-science funds such as Arboretum Ventures and SV Health Investors, which serve as both syndicate partners and sourcing channels.

Publicly available information indicates Charter makes direct investments into operating companies. There is no evidence the firm allocates capital to third-party fund commitments or fund-of-funds structures.

Charter does not invest in software, consumer internet, financial technology, or industrial sectors. Its mandate is explicitly limited to life sciences, encompassing therapeutics, medical devices, diagnostics, and digital-health platforms with a biological or clinical anchor.

Charter actively co-invests with other specialist life-science funds, typically in concentrated syndicates where each investor brings domain-specific board expertise. The firm does not operate as a passive LP in generalist venture funds and prefers to lead or co-lead the rounds it participates in.

The firm's portfolio is concentrated in the United States, with a heavy weighting toward California and Massachusetts. These two states account for the majority of US life-science venture activity and align with Charter's sourcing model, which relies on proximity to academic research centers and clinical talent.